It is known that pentamidine can cause severe pancreatic toxicity in patients with the acquired immunodeficiency syndrome.1 The most frequent and severe adverse event is hypoglycemia that occurs in 6% to 35% of patients assuming pentamidine with a higher incidence in those who are seropositive for the human immunodeficiency virus.2 Occasionally, hyperglycemia and acute pancreatitis have also been reported.3 Diabetes mellitus is a much less commonly recognized complication. Only a few cases have been reported in the literature and the real incidence of diabetes mellitus developing after intravenous pentamidine therapy is unknown.2,4,5
We describe a case of transient diabetes mellitus presenting after pentamidine therapy in a patient with the acquired immunodeficiency syndrome.
Report of a Case.
A 29-year-old man who was an intravenous drug user became infected with the human immunodeficiency virus in 1986. He was admitted to our hospital with a diagnosis of Pneumocystis carinii
Nasti G, Zanette G, Inchiostro S, Donadon V, Tirelli U. Diabetes Mellitus Following Intravenous Pentamidine Administration in a Patient With HIV Infection. Arch Intern Med. 1995;155(6):645–646. doi:10.1001/archinte.1995.00430060109019
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: